10-Q: Artelo Biosciences Reports Q3 Loss, Positive Trial Data, Raises Capital

Artelo Biosciences reported increased net losses and a going concern warning for Q3 2025, despite positive interim clinical trial results for ART27.13 and ART26.12, and successful capital raises.

Summary

• Reported a net loss of $8.7 million for the nine months ended September 30, 2025, compared to $6.0 million for the same period in 2024.
• Cash and cash equivalents stood at $1.7 million as of September 30, 2025, down from $2.3 million at December 31, 2024.
• Operating expenses increased to $8.6 million for the nine months ended September 30, 2025, from $6.3 million in the prior year, driven by higher professional fees for capital raising and increased R&D expenditures.
• Interim results from the Phase 2a CAReS trial for ART27.13 showed a mean body weight increase of 6.38% in patients titrating to the top dose (n=5) compared to a 5.42% loss in placebo (n=6) after 12 weeks.
• Favorable first-in-human study results for ART26.12 indicated mild, transient, self-resolving adverse events and dose-dependent, linear absorption with a wide safety margin.
• Successfully raised capital through multiple offerings, including $0.9 million from convertible notes, $1.1 million net from a private placement, $0.4 million net from an At-The-Market offering, and $2.9 million net from an underwritten offering.
• A subsequent underwritten offering on October 1, 2025, generated approximately $2.0 million in gross proceeds.
• The company adopted a digital asset treasury strategy, acquiring $250,000 in Solana (SOL) tokens, which had a fair value of $325,000 as of September 30, 2025.
• A 1-for-6 reverse stock split was effective on June 13, 2025, and authorized common stock shares were increased from 8,333,333 to 500,000,000 on August 28, 2025.

Sentiment

Score: 3

Explanation: While there are positive clinical trial results and successful capital raises, the company's severe financial deterioration, including a significant net loss, negative working capital, and an explicit going concern warning, overshadows these positives. The termination of a large PIPE offering and the unconventional digital asset strategy add to the financial uncertainty and risk profile.

Positives

• ART27.13 Phase 2a CAReS trial interim results showed compelling increases in mean body weight of 6.38% in the treatment group (n=5) compared to a 5.42% loss in the placebo group (n=6) after 12 weeks, with a maximum weight gain of 18.5%.
• ART27.13 also demonstrated a +4.23% increase in lean body mass in the treatment group versus a -3.15% loss in placebo at one month.
• Safety results for ART27.13 were consistent with prior findings, with only mild or moderate adverse events (22% of participants) and no drug-related serious adverse events reported.
• ART26.12 Phase 1 first-in-human study showed favorable safety and tolerability, with all adverse events being mild, transient, and self-resolving, and no drug-related adverse events observed.
• ART26.12 demonstrated dose-dependent, linear absorption and a wide safety margin, supporting potential titration for maximum efficacy in future studies.
• Successfully raised significant capital through various offerings, including $0.9 million from convertible notes, $1.1 million net from a private placement, $0.4 million net from an At-The-Market offering, and $2.9 million net from an underwritten offering, providing essential funding for operations.
• The company holds an exclusive worldwide license for ART27.13 and intellectual property rights for ART26.12 and ART12.11, including two U.S. patents and six foreign patents for ART12.11.
• Initiated a digital asset treasury strategy by acquiring $250,000 in Solana (SOL) tokens, which appreciated to a fair value of $325,000 by September 30, 2025.

Negatives

• Incurred a substantial net loss of $8.7 million for the nine months ended September 30, 2025, an increase from $6.0 million in the prior year.
• Reported a total stockholders' deficit of $(633) thousand as of September 30, 2025, a significant deterioration from $2.9 million in equity at December 31, 2024.
• Working capital decreased significantly to $(3,033) thousand as of September 30, 2025, from $785 thousand at December 31, 2024.
• Cash and cash equivalents decreased to $1.7 million as of September 30, 2025, from $2.3 million at December 31, 2024.
• Total current liabilities increased substantially to $4.9 million as of September 30, 2025, from $1.8 million at December 31, 2024, partly due to deferring payments to vendors.
• Basic and diluted loss per share increased to $(12.48) for the nine months ended September 30, 2025, from $(11.28) in the prior year.
• A previously announced at-the-market PIPE offering for approximately $9.5 million, intended to fund SOL purchases, was terminated on August 19, 2025, with all proceeds returned to investors.
• Research and development tax credits from the UK Government decreased to $704 thousand for the nine months ended September 30, 2025, from $1,349 thousand in the prior year.

Risks

• Substantial doubt about the ability to continue as a going concern within one year due to incurred losses since inception and insufficient cash to fund future operations.
• Inability to acquire additional funding through equity or debt offerings or licensing product candidates, or that any additional funding would be sufficient to continue operations.
• Exposure to market risks from changes in foreign currency rates due to international operations.
• Potential variability in earnings from holding or selling significant amounts of SOL, as digital asset prices are subject to dramatic price fluctuations and high volatility.
• The company has not adopted a comprehensive digital-asset treasury policy or formal internal controls beyond standard custodial procedures for SOL, and has not authorized staking, lending, pledging, rehypothecating, or deploying SOL for yield.
• Uncertainty regarding the impact of challenging global and national events (tariffs, trade disputes, extreme weather, economic uncertainty, inflation, interest rate fluctuations, financial institution failures, conflicts) on business, operations, and development timelines.
• Future R&D expenses are expected to continue, highly dependent on the scope of preclinical/clinical development and available funding.
• Potential for dilution if additional funds are raised by issuing equity securities.
• Future debt financing may impose restrictive covenants on operations.
• Inability to raise additional funds on favorable terms or at all, potentially due to worsening global economic conditions or market disruptions.
• Challenges and uncertainties may consume available capital resources more rapidly than expected, including delays in product development, changes in R&D investment, intellectual property costs, business strategy changes, infrastructure needs, and geopolitical impacts.

Future Outlook

The company expects to continue incurring future research and development expenses for its drug candidates, with the level of expenses dependent on the scope of development activities and available funding. General and administrative expenses are expected to remain broadly comparable in the near-term. The company will require substantial additional capital to fund operations for the foreseeable future and intends to obtain this through public or private equity offerings, debt financings, credit/loan facilities, or a combination. There is no assurance that additional funding will be successful or sufficient to continue operations.

Management Comments

• Management believes that the disclosures presented are adequate and not misleading.
• Management believes, based upon the quality of the financial institutions, that the credit risk with regard to cash balances in excess of federally insured limits is not significant.
• Management believes the proprietary CBD cocrystal (ART12.11) exists as a single crystal form and is anticipated to have advantages over other solid forms of CBD, including improved stability, solubility, and a more consistent absorption profile.
• Management believes the features of ART12.11 have contributed to a more consistent and improved bioavailability and pharmacokinetic profile, which may ultimately lead to improved safety and efficacy in human therapeutics.
• Management plans to retain rights to internally develop and commercialize products but may seek collaborations when a partnering strategy maximizes stockholder value.

Industry Context

Artelo Biosciences operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, focusing on lipid-signaling pathways and the endocannabinoid system. Its pipeline, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy, addresses significant unmet medical needs. The company's strategy to develop proprietary cocrystal compositions like ART12.11 for CBD aims to differentiate its products in a growing market for cannabinoid-based therapeutics. The recent foray into digital assets with Solana (SOL) tokens represents an unusual and potentially high-risk treasury strategy for a biopharmaceutical company, diverging from traditional industry practices and adding a layer of speculative investment exposure.

Comparison to Industry Standards

• The company's significant net losses and negative working capital are common for clinical-stage biopharmaceutical companies that have not yet brought products to market and are heavily invested in R&D.
• The reliance on frequent capital raises through equity offerings and convertible notes is typical for companies in this stage, though the rapid succession and increasing dilution highlight significant cash burn.
• The positive interim Phase 2a results for ART27.13, showing significant weight gain in cancer-related anorexia, are promising and compare favorably to the lack of effective treatments in this area, potentially positioning it well against existing supportive care options.
• The favorable Phase 1 safety and pharmacokinetic profile for ART26.12 is a standard and necessary step in drug development, indicating a well-tolerated compound, which is a positive sign for progression to later-stage trials for indications like CIPN, where approved treatments are currently lacking.
• The investment in Solana (SOL) tokens as a treasury asset is highly unconventional for a biopharmaceutical company and deviates significantly from standard industry treasury management practices, which typically prioritize capital preservation and liquidity in low-risk assets.

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that are likely to have a material adverse effect on the business, financial condition, and results of operations.

Related Party Transactions

• A company owned by the Senior Vice President, European Operations, provided consulting services totaling $14,000 during the nine months ended September 30, 2025, with $1,000 outstanding.
• A company significantly influenced by a director of a subsidiary provided professional services totaling $71,000 during the nine months ended September 30, 2025, with $24,000 outstanding.
• A company controlled by a director of a subsidiary provided professional services totaling $55,000 during the nine months ended September 30, 2025, with $7,000 outstanding.
• Certain members of the board of directors, an officer, and consultants acquired $350,000 of the $900,000 convertible notes issued on May 1, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution from ongoing equity raises and potential future raises. The reverse stock split aimed to maintain listing, but the going concern warning and increasing losses pose substantial risk to investment value. Positive clinical data offers potential upside, but is highly speculative.
• **Employees:** The company's ability to continue as a going concern directly impacts job security and potential for future compensation, including stock-based incentives.
• **Customers (Future Patients):** Positive clinical trial results for ART27.13 and ART26.12 offer hope for new treatments for cancer-related anorexia and chemotherapy-induced peripheral neuropathy, addressing unmet medical needs.
• **Suppliers/Creditors:** Increased current liabilities and deferred payments to vendors indicate potential payment delays. The going concern warning raises concerns about the company's ability to meet future obligations.
• **Regulatory Authorities:** The company continues to engage with regulatory bodies (e.g., FDA, UK, Ireland, Norway) for clinical trial approvals and potential marketing authorization, indicating ongoing compliance and development efforts.

Next Steps

• Continue research and development activities for product candidates.
• Maintain, protect, and expand the intellectual property portfolio.
• Implement operational, financial, and management information systems.
• Attract, hire, and retain additional management, scientific, and administrative personnel.
• Operate as a public company, including compliance with Nasdaq listing requirements.
• Seek additional funding through public or private equity offerings, debt financings, credit/loan facilities, or a combination.
• Further develop ART27.13 for cancer-related anorexia, potentially advancing to later-stage clinical trials.
• Further develop ART26.12 for chemotherapy-induced peripheral neuropathy and explore other applications like cancer therapeutic, dermatologic conditions, pain/inflammation, and anxiety-related disorders.
• Develop ART12.11 for multiple potential indications such as anxiety disorders (PTSD), depression, epilepsy, and insomnia.
• Monitor and manage the digital asset treasury strategy, including potential future yield generation through staking, subject to Board approval.

Key Dates

Recommendation

Despite some positive clinical trial data for ART27.13 and ART26.12, the company's financial position is severely distressed, evidenced by a substantial net loss, negative working capital, and an explicit 'going concern' warning. While capital has been raised, it has been highly dilutive, and the company continues to burn cash at an accelerated rate. The termination of a significant PIPE offering and the unconventional, volatile digital asset treasury strategy add further layers of risk and uncertainty. For a seasoned investor, the fundamental financial risks and the high probability of further dilution outweigh the early-stage clinical progress, making a 'sell' recommendation prudent to mitigate potential further losses.

Keywords

Biopharmaceutical, Clinical Stage, Endocannabinoid System, ART27.13, Cancer-related Anorexia, CAReS Trial, ART26.12, Chemotherapy-Induced Peripheral Neuropathy, FABP5 Inhibitor, ART12.11, CBD Cocrystal, Solana, SOL Token, Digital Assets, SEC Filing, 10-Q, Financial Results, Capital Raise, Going Concern, Clinical Trials, Drug Development, Biotech, Pharmaceuticals